List view / Grid view
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma's productivity crisis – and why it will take longer than the optimists claim.
AI is moving beyond drug design to answer a critical question: can a promising compound actually be manufactured at scale? By predicting synthetic feasibility early, machine learning tools are helping drug developers avoid costly failures, streamline R&D and design molecules that are both effective and practical to produce.
Porosome Therapeutics have announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Can a cholesterol enzyme help treat an untreatable liver disease? Esperion’s ACLY programme is using multiomic and preclinical data to evaluate its potential in primary sclerosing cholangitis.
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
29 July 2025 | By Eurofins Discovery
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
